Home › Compound Library › Varenicline (Chantix)

Varenicline (Chantix)

Stimulantprescriptionoral · inferred

Selective alpha4-beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. Reduces cravings and withdrawal while blunting the reinforcing effect of nicotine. Standard titration: 0.5 mg daily x3d, 0.5 mg BID x4d, then 1 mg BID. Plasma half-life ~24h. Oral bioavailability high; predominantly renally excreted unchanged. Neuropsychiatric warnings historically present; 2016 EAGLES trial largely reassured.

Projected serum levels — 1 mg, twice daily

Varenicline (Chantix)
Varenicline (Chantix) modeled serum levels, 1 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
Varenicline (Chantix) modeled serum levels with a loading dose of 3 mg, then 1 mg twice daily The first dose is larger so levels approach steady state faster. 0 1.3 2.5 3.8 5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 1 mg twice daily (oral).

Loading schedule: 3 mg on day 1, then 1 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 2.8 mg, trough ≈ 2.2 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Stimulant
Route modeled
Oral
Model confidence
inferred
Half-life
24 h
Common dose
1 mg
Suggested maximum
2 mg/day
Reference dose range
0.50–2 mg (single dose)
Suggested cadence
twice daily
Validated against
1 mg oral — Cmax 0.007 mg/L at 3.5 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Varenicline (Chantix) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Varenicline (Chantix) Serotonin risk

    25I-NBOMe and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Varenicline (Chantix) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Varenicline (Chantix) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Varenicline (Chantix) Serotonin risk

    4-AcO-DMT (Psilacetin) and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Varenicline (Chantix) Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Varenicline (Chantix) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

Serum checks 78 modeled interaction pairings for varenicline (chantix) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics and pharmacodynamics of varenicline Faessel HM et al. · Clinical Pharmacokinetics, 2010 DOI

    Comprehensive PK review establishing varenicline's 24h half-life, high bioavailability, minimal metabolism, and predominantly renal clearance.

  2. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial Jorenby DE et al. · JAMA, 2006 DOI

    Landmark RCT establishing varenicline superior to placebo and bupropion for smoking cessation, leading to FDA approval.

2 published studies referenced in the app, each with a plain-language summary.